# bpd partners

> bpd partners is a VC fund in Prague backing Health Care and Health Diagnostics. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Prague, Czech Republic
- Total investments: 8
- Last investment: Sep 2022
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bpd-partners
- Website: http://www.bpdpartners.cz

bpd partners is a VC fund in Prague focused on Health Care and Health Diagnostics. Bpd partners a.s., is a Czech Family Office founded in 2008 by three Czech entrepreneurs Petr Pudil, Vasil Bobela and Jan Dobrovský. The company's mission is to manage the assets of a group of founding families. Investments by bpd partners are mainly focused on renewable energy, real estate, chemical industry, research and development inhealthcare, biotechnology and agriculture.

## Contacts

5 contacts available for bpd partners. Shizune tracks 3 team members at bpd partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bpd-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 50% |
| Health Diagnostics | 4 | 50% |
| Biotechnology | 3 | 38% |
| Big Data | 2 | 25% |
| Medical Device | 2 | 25% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 38% |
| Venture - Series Unknown | 2 | 25% |
| Pre-Seed | 1 | 13% |
| Series C | 1 | 13% |
| Convertible Note | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 25% |
| Slovakia (Slovak Republic) | 2 | 25% |
| Israel | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jan Dobrovský | Founder | 0 | https://shizune.co/investors/profile/jan-dobrovsk%C3%BD |
| Petr Pudil | Founder & MD | 0 | https://shizune.co/investors/profile/petr-pudil |
| Vasil Bobela | Founder | 0 | https://shizune.co/investors/profile/vasil-bobela |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Powerful Medical | Powerful Medical's PMcardio® is an AI-powered cardiovascular diagnostics and care coordination platform that transforms any 12-lead ECG—paper, scan, image, or digital—into an instant, expert-level diagnostic tool on any smartphone or computer. Powered by Queen of Hearts™, our FDA breakthrough-designated STEMI detection model, PMcardioidentifies true STEMI and STEMI-equivalent patterns with far greater accuracy than traditional criteria. Already used by 100,000 clinicians and detecting 36,000 heart attacks in H1/25 alone, PMcardio has been recognized as a strategic EU priority with a $46M non-dilutive R&D grant, and we are now seeking a $25M partner to commercialize in the U.S.Trained on 2.5 million clinically validated ECGs and proven in 15+ clinical studies, Queen of Hearts™ delivers twice the sensitivity for early STEMI detection and reduces false positives by 90%, cutting door-to-balloon times by an average of 48 minutes. PMcardio closes critical diagnostic gaps—especially in non-PCI and rural settings—ensuring faster, more accurate triage and timely access to life-saving PCI therapy.Powerful Medical has been recognized by the AHA, Google for Startups, and has won the 2025 MedTech Innovator Program! | $9.5M | Seed | Sep 28, 2022 |  |
| Sampling Human | The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinicaldiagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS. | $2M | Seed | Apr 12, 2022 |  |
| Scase | Scase is a diagnostic solution that consists of a portable, point-of-care, medical device combining smart sensors (specifically: contact and contactless thermometer, blood pressure monitor, glucometer and pulse oximeter) with a digital patient database including reminders, tailor-made questionnaires, measurement and drug-taking plans. The solutionconnects to a digital platform that enables two-way communication, visualization and transmission of patient vital data accessible by a healthcare provider, doctor, patient and relatives. | $563.7K | Venture - Series Unknown | Feb 01, 2022 |  |
| Scase | Scase is a diagnostic solution that consists of a portable, point-of-care, medical device combining smart sensors (specifically: contact and contactless thermometer, blood pressure monitor, glucometer and pulse oximeter) with a digital patient database including reminders, tailor-made questionnaires, measurement and drug-taking plans. The solutionconnects to a digital platform that enables two-way communication, visualization and transmission of patient vital data accessible by a healthcare provider, doctor, patient and relatives. | $563.6K | Convertible Note | Sep 15, 2021 |  |
| Scase | Scase is a diagnostic solution that consists of a portable, point-of-care, medical device combining smart sensors (specifically: contact and contactless thermometer, blood pressure monitor, glucometer and pulse oximeter) with a digital patient database including reminders, tailor-made questionnaires, measurement and drug-taking plans. The solutionconnects to a digital platform that enables two-way communication, visualization and transmission of patient vital data accessible by a healthcare provider, doctor, patient and relatives. | $532K | Seed | Jul 27, 2021 |  |
| Groundwork BioAg | Groundwork develops, manufactures and commercializes mycorrhizal inoculants for mainstream agriculture. Their customers achieve significantly higher crop yields, while reducing their environmental impact and saving money on agricultural inputs. | $11M | Venture - Series Unknown | May 12, 2021 |  |
| Scipher Medicine | At Scipher Medicine, we are committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. We have built a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, we canpredict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For our first commercial product, we have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs.We also used a different one for the ACO Payer Summit, I’ve provided that as well: Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy. | $82M | Series C | Mar 24, 2021 |  |
| Powerful Medical | Powerful Medical's PMcardio® is an AI-powered cardiovascular diagnostics and care coordination platform that transforms any 12-lead ECG—paper, scan, image, or digital—into an instant, expert-level diagnostic tool on any smartphone or computer. Powered by Queen of Hearts™, our FDA breakthrough-designated STEMI detection model, PMcardioidentifies true STEMI and STEMI-equivalent patterns with far greater accuracy than traditional criteria. Already used by 100,000 clinicians and detecting 36,000 heart attacks in H1/25 alone, PMcardio has been recognized as a strategic EU priority with a $46M non-dilutive R&D grant, and we are now seeking a $25M partner to commercialize in the U.S.Trained on 2.5 million clinically validated ECGs and proven in 15+ clinical studies, Queen of Hearts™ delivers twice the sensitivity for early STEMI detection and reduces false positives by 90%, cutting door-to-balloon times by an average of 48 minutes. PMcardio closes critical diagnostic gaps—especially in non-PCI and rural settings—ensuring faster, more accurate triage and timely access to life-saving PCI therapy.Powerful Medical has been recognized by the AHA, Google for Startups, and has won the 2025 MedTech Innovator Program! | $3.3M | Pre-Seed | Jun 01, 2020 |  |

8 of 8 investments shown.

## Co-investors
- [Look AI Investments (formerly AI Startup Incubator)](https://shizune.co/investors/profile/ai-startup-incubator) — VC Fund, 2 deals together
- [Venture to Future Fund](https://shizune.co/investors/profile/venture-to-future-fund) — VC Fund, 2 deals together
- [Y Soft Ventures](https://shizune.co/investors/profile/y-soft-ventures) — VC Fund, 2 deals together
- [Zero One Hundred](https://shizune.co/investors/profile/zero-gravity-capital-0c47) — VC Fund, 2 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 1 deal together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does bpd partners invest in?

bpd partners invests primarily in Health Care, Health Diagnostics and Biotechnology startups, most often at Seed and Venture - Series Unknown stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact bpd partners?

Public channels for bpd partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at bpd partners?

The team at bpd partners includes Jan Dobrovský (Founder), Petr Pudil (Founder & MD) and Vasil Bobela (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co